Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 2Leukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Chemotherapy Induced Neutropenia 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 37Radiotherapy 31Oxaliplatin 29Cisplatin 28Paclitaxel 24Leucovorin 22Irinotecan 19Docetaxel 13pembrolizumab 10Capecitabine 10Carboplatin 9Radiation 8Neoadjuvant Therapy 8Cetuximab 8Surgical Procedures, Operative 7Folfox protocol 7Chemotherapy, Adjuvant 6Nivolumab 5Gefitinib 5Taxes 4Erlotinib Hydrochloride 4Biopsy 4durvalumab 3Panitumumab 3Itraconazole 3Epirubicin 3Bevacizumab 3tremelimumab 2spartalizumab 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma Of Esophagus × pegylated granulocyte colony-stimulating factor, human × Clear all
NCT00069953 2017-02-17

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Radiation Therapy Oncology Group

Phase 2 Completed
43 enrolled 5 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡